How Recursion is leading a new era of AI-driven drug discovery AI drug discovery is not a new phenomenon – but it is evolving at an almost dizzying pace. Recursion is one of the earliest innovators in ...

In early December 2025, Recursion Pharmaceuticals released clinical data from the TUPELO Phase 1b/2 trial of REC-4881, providing fresh insight into the candidate’s safety and efficacy profile. This ...

Shares of Recursion Pharmaceuticals, Inc. (NASDAQ: RXRX) are trading higher Monday after the pharmaceutical company reported positive data from an ongoing trial. What To Know: Recursion ...

In one of the biggest M&A deals involving artificial intelligence-focused drug developers to date, Recursion Pharma has agreed to join with Exscientia in an all-stock transaction valued at $688 ...

Recursion Pharmaceuticals, Inc. remains a Sell as pipeline progress, notably REC-4881 in FAP, fails to surpass cheap alternatives like Celebrex. REC-4881's Phase 1/2 data show a median polyp reduction ...

Meetings at work can be stressful spaces to speak. Do you struggle to talk about your ideas in meetings? Do you know how to interrupt politely? In this episode of Office English, Pippa and Phil talk ...

The English We Speak is your chance to catch up on the very latest English words and phrases. In under 3 minutes, we help you stay ahead of the pack by giving you 'must have' phrases that you can use ...

FUKUOKA -- In September 2025, a group of people shouted at Muslims in front of a mosque in Fukuoka, telling them to "get out of Japan." This happened Full article News in Easy English: Japan expert ...